Neogene Therapeutics is a pre-clinical stage biotechnology company, with offices in Santa Monica, CA and Amsterdam, Netherlands, aiming to change the paradigm of treatment for solid cancers. Our mission is to provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens, which are present on cancer cells as a consequence of DNA mutations. Neogene is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.
Location: Netherlands, North Holland, Amsterdam
Employees: 11-50
Total raised: $110M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | Vida Ventu... | vidaventur... |
| - | Jeito Capi... | jeito.life |
| - | Two River ... | tworiver.c... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Syncona Pa... | synconaltd... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.09.2020 | Series A | $110M | - |
Mentions in press and media 13
| Date | Title | Description |
| 18.05.2023 | Startup Showcase: Neogene Therapeutics – Pioneering T Cell Therapies for Cancer | Welcome to our startup showcase featuring Neogene Therapeutics, a biotech company based in Amsterdam, The Netherlands. Neogene Therapeutics is at the forefront of cancer treatment, providing innovative T cell therapies that target mutated p... |
| 16.01.2023 | Acquisition of Neogene Therapeutics completed | Acquisition of Neogene Therapeutics completed Mon, Jan 16, 2023 08:00 CET Report this content 16 January 2023 07:00 GMT Acquisition of Neogene Therapeutics completed AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Ne... |
| 29.11.2022 | AstraZeneca to acquire Neogene Therapeutics | AstraZeneca to acquire Neogene Therapeutics Tue, Nov 29, 2022 08:04 CET Report this content 29 November 2022 7:00 GMT AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy Acquisition provides access to... |
| 06.10.2020 | Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors | Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK & AMSTERDAM–(BUSINESS WIRE)–October 6, 2020– Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully person... |
| 16.09.2020 | SYNCONA LIMITED Syncona : Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies | Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The f... |
| 14.09.2020 | Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies | Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The f... |
| 14.09.2020 | Neogene Therapeutics Raises $110 Million Series A Financing | NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised ... |
| 14.09.2020 | Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies | - |
| 14.09.2020 | Amsterdam-based Neogene Therapeutics raises $110M Series A funding to treat cancer patients with personalized neo-antigen T cell therapies | Neogene Therapeutics, an Amsterdam-based biotech startup today announced it has raised $110 million in a Series A financing to develop a new class of fully personalized neo-antigen T cell therapies to treat cancer. The round was co-led by E... |
| 14.09.2020 | Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies | Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes... |
Show more